Merck Inc., has announced new Research data on a Phase 1b study evaluating KEYTRUDA; (Pembrolizumab).
The said medicine is used in advanced non-small cell lung cancer (NSCLC).
View the full release here.
Merck Inc., has announced new Research data on a Phase 1b study evaluating KEYTRUDA; (Pembrolizumab).
The said medicine is used in advanced non-small cell lung cancer (NSCLC).
View the full release here.